Sector News

Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m

January 23, 2021
Life sciences

Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash.

Founded 20 years ago, Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.

Thermo Fisher executive vice-president Michel Lagarde said: “The addition of their manufacturing capabilities in Europe complements our four development and manufacturing sites in North America.

“In addition, they bring an incredibly talented team with more than two decades of experience across a broad range of viral vectors.

“The combination will benefit our global customers seeking support and capacity in the region as well as European customers bringing new medicines to patients inside and outside of Europe.”

The viral vector manufacturing business offers over 7,000m² of advanced clinical and commercial manufacturing capacity.

With two locations in Seneffe and Gosselies, Henogen has around 400 employees with extensive operational and technical proficiency in various viral vector classes.

Novasep president and CEO Michel Spagnol said: “Our diverse customer base will benefit from the combination of our viral vector services capabilities with the scale and capabilities of Thermo Fisher.

“Our talented employees will bring deep expertise to an organisation that shares our commitment to providing ground-breaking new medicines to patients.”

The business will be part of the Pharma Services business within the Laboratory Products and Services Segment.

In March 2019, Thermo Fisher Scientific signed a definitive agreement to acquire viral vector manufacturing company Brammer Bio for a cash consideration of around $1.7bn.

Brammer Bio is focused on the clinical and commercial supply of vectors for in vivo gene therapy and ex vivo gene-modified cell therapy.

by Pharmaceutical-Technology.com

Source: pharmaceutical-technology.com

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”